

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

UCB, INC., UCB BIOPHARMA SPRL,
RESEARCH CORPORATION TECHNOLOGIES,
INC. and HARRIS FRC CORPORATION,

Plaintiffs,

v.

ACCORD HEALTHCARE, INC., et al.,

Defendants.

C.A. No. 13-1206-LPS
CONSOLIDATED

UCB, INC., UCB BIOPHARMA SPRL,
RESEARCH CORPORATION TECHNOLOGIES,
INC. and HARRIS FRC CORPORATION,

Plaintiffs,

v.

AMNEAL PHARMACEUTICALS LLC
and AMNEAL PHARMACEUTICALS OF NEW
YORK, LLC,

Defendants.

C.A. No. 13-1208-LPS

UCB, INC., UCB BIOPHARMA SPRL,
RESEARCH CORPORATION TECHNOLOGIES,
INC. and HARRIS FRC CORPORATION,

Plaintiffs,

v.

AUROBINDO PHARMA LTD. and AUROBINDO
PHARMA USA, INC.,

Defendants.

C.A. No. 13-1210-LPS

UCB, INC., UCB BIOPHARMA SPRL,
RESEARCH CORPORATION TECHNOLOGIES,
INC. and HARRIS FRC CORPORATION,

Plaintiffs,

v.

BRECKENRIDGE PHARMACEUTICAL, INC. and
MSN LABORATORIES PVT. LTD.,

Defendants.

C.A. No. 13-1211-LPS

UCB, INC., UCB BIOPHARMA SPRL,
RESEARCH CORPORATION TECHNOLOGIES,
INC. and HARRIS FRC CORPORATION,

Plaintiffs,

v.

SUN PHARMA GLOBAL FZE and SUN
PHARMACEUTICAL INDUSTRIES, LTD.,

Defendants.

C.A. No. 13-1218-LPS

UCB, INC., UCB BIOPHARMA SPRL,
RESEARCH CORPORATION TECHNOLOGIES,
INC. and HARRIS FRC CORPORATION,

Plaintiffs,

v.

WATSON LABORATORIES, INC., – FLORIDA
(n/k/a ACTAVIS LABORATORIES FL, INC.),
WATSON PHARMA, INC. (n/k/a ACTAVIS
PHARMA, INC.), and ACTAVIS, INC.,

Defendants.

C.A. No. 13-1219-LPS

NOTICE OF APPEAL

Notice is hereby given that Defendants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc., – Florida (n/k/a Actavis Laboratories FL, Inc.), Watson Pharma, Inc. (n/k/a Actavis Pharma, Inc.), and Actavis, Inc. appeal to the United States Court of Appeals for the Federal Circuit from the Final Judgment entered on September 1, 2016 (D.I. 323 in C.A. No. 13-1206; D.I. 24 in C.A. No. 13-1208; D.I. 28 in C.A. No. 13-1210; D.I. 30 in C.A. No. 13-1211; D.I. 23 in C.A. No. 13-1218; D.I. 28 in C.A. No. 13-1219), and all underlying orders, rulings, and findings made prior to, during, and after trial, including but not limited to the Opinion and Order entered on August 12, 2016 (D.I. 313 and 314 in C.A. No. 13-1206) and the Memorandum Opinion and Order entered on May 14, 2015 (D.I. 240 and 241 in C.A. No. 13-1206). Included herewith is payment of the filing fee (\$5.00) and the docketing fee (\$500.00) as required by 28 U.S.C. § 1917 and Federal Circuit Rule 52(a)(3)(A), and Federal Rule of Appellate Procedure 3(e).

Dated: September 22, 2016

PHILLIPS GOLDMAN MCLAUGHLIN & HALL, P.A.

/s/ John C. Phillips, Jr.

John C. Phillips, Jr. (#110)

Megan C. Haney (#5016)

1200 North Broom Street

Wilmington, DE 19806

(302) 655-4200

jcp@pgmhlaw.com

mch@pgmhlaw.com

Of Counsel:

WINSTON & STRAWN LLP

George C. Lombardi

Maureen L. Rurka

Samuel S. Park

John R. McNair

35 West Wacker Drive

Chicago, IL 60601

Charles B. Klein

Eimeric Reig-Plessis

1700 K Street, N.W.

Washington, DC 20006

Attorneys for Defendants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc., – Florida (n/k/a Actavis Laboratories FL, Inc.), Watson Pharma, Inc. (n/k/a Actavis Pharma, Inc.), and Actavis, Inc.